ArticleJournal of diabetes investigation2025

Cardiovascular and kidney benefits of GLP-1 receptor agonists across large randomized placebo-controlled trials.

Satoshi Yoshiji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.